197 related articles for article (PubMed ID: 31767898)
1. Author Correction: Anticancer polymers designed for killing dormant prostate cancer cells.
Takahashi H; Yumoto K; Yasuhara K; Nadres ET; Kikuchi Y; Buttitta L; Taichman RS; Kuroda K
Sci Rep; 2019 Nov; 9(1):17455. PubMed ID: 31767898
[TBL] [Abstract][Full Text] [Related]
2. Author Correction: Coupling Chlorin e6 to the surface of Nanoscale Gas Vesicles strongly enhances their intracellular delivery and photodynamic killing of cancer cells.
Fernando A; Gariépy J
Sci Rep; 2020 Oct; 10(1):19104. PubMed ID: 33127968
[TBL] [Abstract][Full Text] [Related]
3. Author Correction: MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.
Yasumizu Y; Rajabi H; Jin C; Hata T; Pitroda S; Long MD; Hagiwara M; Li W; Hu Q; Liu S; Yamashita N; Fushimi A; Kui L; Samur M; Yamamoto M; Zhang Y; Zhang N; Hong D; Maeda T; Kosaka T; Wong KK; Oya M; Kufe D
Nat Commun; 2020 Feb; 11(1):1095. PubMed ID: 32094369
[TBL] [Abstract][Full Text] [Related]
4. Author Correction: Evaluation of T1 relaxation time in prostate cancer and benign prostate tissue using a Modified Look-Locker inversion recovery sequence.
Baur ADJ; Hansen CM; Rogasch J; Posch H; Elezkurtaj S; Maxeiner A; Erb-Eigner K; Makowski MR
Sci Rep; 2020 Mar; 10(1):5249. PubMed ID: 32184409
[TBL] [Abstract][Full Text] [Related]
5. Author Correction: The Kunitz Domain I of Hepatocyte Growth Factor Activator Inhibitor-2 Inhibits Matriptase Activity and Invasive Ability of Human Prostate Cancer Cells.
Wu SR; Teng CH; Tu YT; Ko CJ; Cheng TS; Lan SW; Lin HY; Lin HH; Tu HF; Hsiao PW; Huang HP; Chen CH; Lee MS
Sci Rep; 2020 Feb; 10(1):2874. PubMed ID: 32051516
[TBL] [Abstract][Full Text] [Related]
6. Author Correction: Modeling ErbB2-p130Cas interaction to design new potential anticancer agents.
Costamagna A; Rossi Sebastiano M; Natalini D; Simoni M; Valabrega G; Defilippi P; Visentin S; Ermondi G; Turco E; Caron G; Cabodi S
Sci Rep; 2019 Nov; 9(1):17729. PubMed ID: 31758081
[TBL] [Abstract][Full Text] [Related]
7. Author Correction: FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes.
Adams EJ; Karthaus WR; Hoover E; Liu D; Gruet A; Zhang Z; Cho H; DiLoreto R; Chhangawala S; Liu Y; Watson PA; Davicioni E; Sboner A; Barbieri CE; Bose R; Leslie CS; Sawyers CL
Nature; 2020 Sep; 585(7826):E20. PubMed ID: 32895534
[TBL] [Abstract][Full Text] [Related]
8. Author Correction: Genomic Prediction of 16 Complex Disease Risks Including Heart Attack, Diabetes, Breast and Prostate Cancer.
Lello L; Raben TG; Yong SY; Tellier LCAM; Hsu SDH
Sci Rep; 2019 Nov; 9(1):17515. PubMed ID: 31748697
[TBL] [Abstract][Full Text] [Related]
9. Author Correction: The evolutionary history of lethal metastatic prostate cancer.
Gundem G; Van Loo P; Kremeyer B; Alexandrov LB; Tubio JMC; Papaemmanuil E; Brewer DS; Kallio HML; Hägnäs G; Annala M; Kivinummi K; Goody V; Latimer C; O'Meara S; Dawson KJ; Isaacs W; Emmert-Buck MR; Nykter M; Foster C; Kote-Jarai Z; Easton D; Whitaker HC; ; Neal DE; Cooper CS; Eeles RA; Visakorpi T; Campbell PJ; McDermott U; Wedge DC; Bova GS
Nature; 2020 Aug; 584(7820):E18. PubMed ID: 32728210
[TBL] [Abstract][Full Text] [Related]
10. Author Correction: Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.
Carver BS; Tran J; Gopalan A; Chen Z; Shaikh S; Carracedo A; Alimonti A; Nardella C; Varmeh S; Scardino PT; Cordon-Cardo C; Gerald W; Pandolfi PP
Nat Genet; 2020 Sep; 52(9):984. PubMed ID: 32820258
[TBL] [Abstract][Full Text] [Related]
11. Author Correction: An exome-wide rare variant analysis of Korean men identifies three novel genes predisposing to prostate cancer.
Oh JJ; Shivakumar M; Miller J; Verma S; Lee H; Hong SK; Lee SE; Lee Y; Lee SJ; Sung J; Kim D; Byun SS
Sci Rep; 2020 Feb; 10(1):2481. PubMed ID: 32034279
[TBL] [Abstract][Full Text] [Related]
12. Author Correction: Evaluation of Radiation dosimetry of
Zhang J; Zhang J; Xu X; Lu L; Hu S; Liu C; Cheng J; Song S; Zhang Y; Shi LQ
Sci Rep; 2020 Oct; 10(1):18494. PubMed ID: 33097773
[TBL] [Abstract][Full Text] [Related]
13. Author Correction: A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer.
Lunardi A; Ala U; Epping MT; Salmena L; Clohessy JG; Webster KA; Wang G; Mazzucchelli R; Bianconi M; Stack EC; Lis R; Patnaik A; Cantley LC; Bubley G; Cordon-Cardo C; Gerald WL; Montironi R; Signoretti S; Loda M; Nardella C; Pandolfi PP
Nat Genet; 2020 Oct; 52(10):1132. PubMed ID: 32884149
[TBL] [Abstract][Full Text] [Related]
14. Author Correction: Genetic alterations in the 3q26.31-32 locus confer an aggressive prostate cancer phenotype.
Simpson BS; Camacho N; Luxton HJ; Pye H; Finn R; Heavey S; Pitt J; Moore CM; Whitaker HC
Commun Biol; 2020 Oct; 3(1):570. PubMed ID: 33033409
[TBL] [Abstract][Full Text] [Related]
15. Author Correction: Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer.
Luszczak S; Simpson BS; Stopka-Farooqui U; Sathyadevan VK; Echeverria LMC; Kumar C; Costa H; Haider A; Freeman A; Jameson C; Ratynska M; Ben-Salha I; Sridhar A; Shaw G; Kelly JD; Pye H; Gately KA; Whitaker HC; Heavey S
Sci Rep; 2020 Nov; 10(1):19870. PubMed ID: 33177621
[TBL] [Abstract][Full Text] [Related]
16. Author Correction: LRIG1 is a pleiotropic androgen receptor-regulated feedback tumor suppressor in prostate cancer.
Li Q; Liu B; Chao HP; Ji Y; Lu Y; Mehmood R; Jeter C; Chen T; Moore JR; Li W; Liu C; Rycaj K; Tracz A; Kirk J; Calhoun-Davis T; Xiong J; Deng Q; Huang J; Foster BA; Gokhale A; Chen X; Tang DG
Nat Commun; 2020 Jun; 11(1):2895. PubMed ID: 32499578
[TBL] [Abstract][Full Text] [Related]
17. Author Correction: Straightforward preparation of supramolecular Janus nanorods by hydrogen bonding of end-functionalized polymers.
Han S; Pensec S; Yilmaz D; Lorthioir C; Jestin J; Guigner JM; Niepceron F; Rieger J; Stoffelbach F; Nicol E; Colombani O; Bouteiller L
Nat Commun; 2020 Oct; 11(1):5141. PubMed ID: 33033252
[TBL] [Abstract][Full Text] [Related]
18. Author Correction: Early Cellular Responses of Prostate Carcinoma Cells to Sepantronium Bromide (YM155) Involve Suppression of mTORC1 by AMPK.
Danielpour D; Gao Z; Zmina PM; Shankar E; Shultes BC; Jobava R; Welford SM; Hatzoglou M
Sci Rep; 2019 Oct; 9(1):14826. PubMed ID: 31597941
[TBL] [Abstract][Full Text] [Related]
19. Author Correction: Comparison of Multipulse Laser Vaporesection versus Plasmakinetic Resection for Treatment of Benign Prostate Obstruction.
Hsu FS; Chou CW; Chang HC; Tu YP; Sha SJ; Chung HH; Huang KH
Sci Rep; 2019 Nov; 9(1):17872. PubMed ID: 31767913
[TBL] [Abstract][Full Text] [Related]
20. Author Correction: Introducing PIONEER: a project to harness big data in prostate cancer research.
Omar MI; Roobol MJ; Ribal MJ; Abbott T; Agapow PM; Araujo S; Asiimwe A; Auffray C; Balaur I; Beyer K; Bernini C; Bjartell A; Briganti A; Butler-Ransohoff JE; Campi R; Cavelaars M; De Meulder B; Devecseri Z; Voss MD; Dimitropoulos K; Evans-Axelsson S; Franks B; Fullwood L; Horgan D; Smith EJ; Kiran A; Kivinummi K; Lambrecht M; Lancet D; Lindgren P; MacLennan S; MacLennan S; Nogueira MM; Moen F; Moinat M; Papineni K; Reich C; Reiche K; Rogiers S; Sartini C; van Bochove K; van Diggelen F; Van Hemelrijck M; Van Poppel H; Zong J; N'Dow J;
Nat Rev Urol; 2020 Aug; 17(8):482. PubMed ID: 32587405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
